Latest Vascular endothelial growth factor Stories
Following several years of study, investigators have found more evidence that viral therapy to treat solid tumors can be enhanced by blocking the body’s natural immune response. Oncolytic viruses have shown promise as anticancer agents, with variations of the herpes simplex virus (HSV) among the most commonly used. However, many studies have shown that the effectiveness of viral therapy to eradicate tumors has not been as successful with patients as it has been in the lab. These results...
LEUVEN, Belgium, February 28, 2013 /PRNewswire/ -- ThromboGenics NV (Euronext Brussels: THR), and co-development partner BioInvent International AB (OMXS: BINV), announce today the publication of a paper in the prestigious journal Cell, highlighting the potential of TB-403 to improve the treatment of medulloblastoma, the most common brain tumor in children. The Cell publication highlights for the first time a new mechanism of action, showing that PlGF plays a vital role...
GREENWOOD VILLAGE, Colo., Feb. 27, 2013 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE) announced oral dosing of the first patient in a 505(b)(2) clinical trial of the investigational drug Optina in diabetic macular edema. The trial will evaluate Optina(TM) in adults with recent onset diabetic macular edema. Last year, the FDA granted Optina(TM) 505(b)(2) status and drugs designated under this pathway can be approved on a single trial. (Logo:...
TARRYTOWN, N.Y. and BERLIN, Feb. 19, 2013 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Bayer HealthCare today announced that they have initiated a new Phase 3 trial (named VIVID EAST-DME) to evaluate the efficacy and safety of EYLEA(®) (aflibercept) Injection in the treatment of Diabetic Macular Edema (DME) in Russia, China, and other Asian countries. The companies are extending their global development program for EYLEA in DME after promising results in the...
A lack of the protein endoglin in the blood vessels of tumor-bearing mice enables the spread of daughter tumors, according to researchers at Karolinska Institutet and Lund University in Sweden in a study published in the scientific periodical The Journal of Experimental Medicine. Given that the tumor vasculature constitutes an important barrier to the spread of cancer cells, the team suggests that drugs should be developed to strengthen the blood vessels' protective function. Studies of...
GREENWOOD VILLAGE, Colo., Jan. 22, 2013 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE) announced today that the FDA has accepted the Company's IND for Optina(TM) for the treatment of diabetic macular edema (DME). Ampio plans to commence enrollment in a clinical trial in the first quarter of 2013. The FDA granted Optina(TM) 505(b)(2) status in July, 2012. Drugs designated under this pathway can be approved on a single trial. (Logo:...
New research in Nature concludes the eye – which depends on light to see – also needs light to develop normally during pregnancy. Scientists say the unexpected finding offers a new basic understanding of fetal eye development and ocular diseases caused by vascular disorders – in particular one called retinopathy of prematurity that can blind premature infants. The research, led by scientists at Cincinnati Children's Hospital Medical Center and the University of California, San...
CINCINNATI, Jan. 16 2013 /PRNewswire-USNewswire/ -- New research in Nature concludes the eye - which depends on light to see - also needs light to develop normally during pregnancy. (Logo: http://photos.prnewswire.com/prnh/20110406/MM79025LOGO) Scientists say the unexpected finding offers a new basic understanding of fetal eye development and ocular diseases caused by vascular disorders - in particular one called retinopathy of prematurity that can blind premature infants. The...
ROCKVILLE, Md., Jan. 7, 2013 /PRNewswire/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, announced today that EntreMed has submitted a new drug clinical trial application with China's State Food and Drug Administration (SFDA) for its proprietary drug candidate, ENMD-2076, to conduct global clinical trials in triple-negative breast cancer patients. (Logo:...
redOrbit Staff & Wire Reports - Your Universe Online A team of US researchers has reportedly developed a way to reprogram scar tissue from damaged hearts into healthy muscle through gene therapy -- a discovery which could help strengthen hearts harmed as a result of cardiovascular events. According to a recent statement, scientists from Weill Cornell Medical College, along with colleagues from the Baylor College of Medicine (BCM) and Stony Brook University Medical Center have...
